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Lentiviral Manipulation of Gene Expression in Human Adult
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ABSTRACT
Human stem cells could revolutionize the field of medicine by providing a diverse range of cell types for
tissue replacement therapies and drug discovery. To achieve this goal, genetic tools need to be optimized
and developed for controlling and manipulating stem cells ex vivo. Here we describe a lentiviral delivery
system capable of high infection rates in human mesenchymal and embryonic stem cells. The lentiviral
backbone was modified to express mono- and bi-cistronic transgenes and was also used to deliver short
hairpin ribonucleic acid for specific silencing of gene expression in human stem cells. We show that
lentiviral transduction can be used to alter gene expression without altering the genes’ ability to differ-
entiate in vitro. These vectors will enable rapid analysis of gene function in stem cells and permit the
generation of knock-in / knock-out models of human disease in the rapidly developing field of gene
therapy.
INTRODUCTION
THE THERAPEUTIC USE of stem cells has the potential totreat a wide range of clinical conditions where existing
conventional therapies have proved inadequate. In animal
models, it has been shown that stem cells can generate
clinically useful cell types, such as insulin-producing cells
for the treatment of diabetes1 and dopamine-producing
cells to cure Parkinson’s disorders.2 However, our limited
understanding of the mechanisms controlling stem cell self-
renewal and fate determination hampers the translation of
these results into clinical therapies, prohibiting the pro-
duction of pure populations of defined cell types in clini-
cally relevant quantities. Additional barriers preventing the
clinical use of stem cells, such as the immune rejection of
grafted cells, also need to be overcome.3 The limited prog-
ress in these areas is due in part to the lack of efficient
genetic tools allowing the versatile manipulation of human
stem cell gene expression.
Lentiviral-based vectors can efficiently transduce a wide
range of cell types, including cells that are post-mitotic and
non-dividing.4 This technology can successfully manipu-
late murine embryonic stem cells, in which transgenes
expressed from lentiviruses are not silenced during differ-
entiation.5,6 Progress was recently made in translating this
technology to human stem cells. Several studies have dem-
onstrated long-term expression of single transgenes in hu-
man stem cells using simple lentiviral constructs.7,8 In
addition, progress in the field of ribonucleic acid (RNA)
interference has also demonstrated that lentivirally delivered
short hairpin RNA (shRNA) is an effective tool for inhibit-
ing gene expression in stem cells.9 These advances have
raised the potential of developing vectors that are capable of
complex manipulation of stem cell gene expression.
Here we describe the development of a series of lentiviral
vectors permitting complex manipulation of gene expression
in human adult and embryonic stem cells. The vectors permit
the delivery of mono- and bi-cistronic transgenes, providing
long-term expression that is maintained throughout differ-
entiation. By modifying the lentiviral backbone to deliver
functional shRNA, we are able to demonstrate the inhibition
of specific exogenous and endogenous gene expression. We
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also show that, by combining both technologies, it is pos-
sible to specifically knock-down and knock-in gene targets
using a single vector. This technology could be used to
generate complex knock-in / knock-out models of human
disease and to control the stem cell fate of medically im-
portant cell types and tissues.
MATERIALS AND METHODS
Cell isolation, culture, and differentiation
Human mesenchymal stem cells (MSCs) were isolated,
cultured, and differentiated into osteocytes and adipocytes
as previously described10 and showed the expected cell
surface marker profile. MSCs were handled in accordance
with local ethical guidelines. Human embryonic stem cell
(hESC) lines H9 and HSF-6 were cultured under conditions
as previously described, and cells were shown to express
the appropriate cell surface markers. HEK293t cells were
cultured in Dulbecco’s Modified Eagle Medium (DMEM)
with 10% Fetal Calf Serum and 100 U/mL penicillin and
streptomycin (Gibco BRL, Gaithersburg, MD).
Lentiviral vector plasmid construction
All lentiviral vectors were based upon the pHR-CMV-
LacZ lentiviral backbone (a gift of D. Trono), the pHR-
CSGW vector (a gift from Adrian Thrasher, modified by
Yasuhiro Ikeda), and the pSIN-Puro vector (a gift from Greg
Towers). pHR-CMV-MCS-IRES-GFP was created by in-
serting the complete encephalomyocarditis virus IRES re-
moved from the pTRIDENT vector11 into pHR-CMV-LacZ
between the XhoI and KpnI (blunted) sites. Green fluores-
cent protein (GFP) was removed from pHR-CMV-GFP (gift
from JB Rascle) using BamHI(blunted)-XbaI digestion, and
inserted into pHR-CMV-IRES cut with KpnI (blunted)-
XbaI. The multiple cloning site was inserted by annealing
primers MCS_F 50-GGATCCGCGGTATACTA GTCGA
CCCGGGTGGCCACTCGAG-30 and MCS_B 50-CTCGA
GTGGCCACCCGGGTCGACTAGTATACCGCGGATCC-
30 digesting with BamHI and XhoI, and ligating into pHR-
CMV-IRES-eGFP cut with BamHI and XhoI.
The pSIN-RIG() vector was created by removing the
BamHI-NotI(blunted) fragment from plasmid pDsRedN1
(Clontech, Mountain View, CA) and ligating into the
BamHI-XhoI (blunted) backbone of pHR-CMV-MCS-IRES-
GFP. The BamHI-XbaI (blunted) fragment was then ligated
into the BamHI-XhoI (blunted) backbone of pHR-CSGW.
pHR-SIN-RIG(þ) was created by introducing a 50-bp se-
quence (50-atcgactctctgagtacatgcattaccacctgtgagtactatgtagt
ca-30) into the XhoI of pHR-CMV-MCS-IRES-GFP and
subcloning as above into the pHR-CSGW backbone.
The pMIN-CMV vector was created by digesting pHR-
CMV-MCS-IRES-GFP with XbaI and BamHI, blunting,
and religation. The other pMIN vectors were created by
digesting pHR-CMV-MCS-IRES-GFP with XbaI and ClaI,
blunting and inserting using SacI/XhoI fragment (blunted)
of pCG3-EF1a (a gift of JB Rascle), the spleen focus form-
ing virus (SFFV) promoter (removed from pCSGW using
EcoRI / BamHi blunted), or the b-actin promoter ClaI /
BamHI (removed from pbactin-GFP, a gift from JB Ras-
cle). To create the pMIN-eGFP vectors, eGFP was cloned
from pCSGW using BamHI (blunted)-NotI (blunted) into
the XbaI site (blunted).
Lentiviral shRNA construction
pSIN-CSGW and pSIN-Puro were modified to contain a
short hairpin sequence by cloning the human U6 promoter
from human BC3 cells into the PstI and NsiII sites in
pGEM and adding SalI and XbaI sites for hairpin insertion
to create pGEM-U6 using PCR primers U6 forward 50-
GGGCTGCAGAAGGTCGGGCAGGAAGAGGGCCTATT
TCCC-30 and U6 reverse 50-GTTCCAATATGCATAAAA
AATCTAGAGAAGCGTCGACGGTGTTTCGTCCTTTC
CACAAG-30. A sequence was added to include EcoRI and
BamHI sites by annealing the oligos U6LinkerF 50-CGA
GCTCAGGATCCTGAATTCGATGCA-30 and U6LinkerR
50-TCGAATTCAGGAT CCTGAGCTCGTGCA-30 and in-
serting this into the Nsi I sites. Short hairpin oligos were
designed as detailed in the figures to include a 50 blunt end, a
TTCG loop, a five T U6 termination sequence, and a 30 XbaI
site (e.g., for DsRed [target TAATGCAGAAGAAGACC
ATGGG], 50-TAATGCAGAAGAAGACCATGGGTTCGC
CCATGGTCTTCTTCTGCATTACTTTTT-30 50-CTAGA
AAAAGTAATGCAGAAGAAGACCATGGGCGAACCC
ATGGTCTTCTTCTGCATT-30).
pGEM-U6L was digested using SalI, blunted using
Mung Bean Nuclease, and then digested using XbaI. An-
nealed short hairpin sequences were then ligated into this
vector to make pGEM-U6-sh. pGEM-U6-sh was digested
using EcoRI, and the 300-bp fragment containing the U6
promoter and short hairpin was ligated into an EcoRI digest
of pSIN-eGFP or pSIN-Puro to make pSINeGFP-sh and
pSINPuro-sh. The activity of the insert was orientation
independent (data not shown).
Lentiviral vector production
Lentiviral production was established as previously de-
scribed.12 One mg of lentiviral plasmids p8.91 and pMD.G
(both gifts from D. Trono) and pSIN or pHR plasmids
(1.5 mg) were co-transfected into HEK293t cells seeded at
8106 cells in a 10-cm dish 24 h before transfection. Media
was changed on the 293t cells 1 h before transfection. The
supernatant containing lentiviral vector particles was har-
vested 60 h after transfection. Viral titer was assessed in
terms of 293t infectious units and was determined using
serial dilution of lentiviral supernatant and infection of
2105 293t cells in a 6-well format. After infection,
quantitative polymerase chain reaction (qPCR) was used to
determine the number of integrated viral copies by qPCR.
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qPCR quantification of viral titers
qPCR was performed using an ABI TaqManPrism 7000
machine. Primers used for detection of lentiviral packaging
complementary DNA are as follows: forward 50-ACTT
FGAAAGCGAAAGGGAAACCA-30; reverse 50-GTGCGC
GCTTCAGCAA-30; concentration 300 pM forward/300
pM reverse. Human glyceraldehyde phosphate dehydroge-
nase (GAPDH): forward 50-GGAGTCAACGGATTTGG
TCGTA-30; reverse 50-GGCAACAATATCCACTTTACC
AGAGT-30; probe 50-CGCCTGGTCACCAGGGCTGC-30;
pM forward /700 pM reverse. All reactions were performed
using SYBR green (Affymetrix, Santa Clara, CA) at the
concentrations indicated. These conditions were shown
through optimization to be sensitive and specific and with
no primer-dimer formation. Standard TaqMan cycling con-
ditions were used throughout.
Lentiviral infection protocol
Infection of MSCs was accomplished as follows. Lenti-
viral vectors were diluted into 1 mL of DMEM (for infection
in a 6-well plate) or 5 mL DMEM (for infection in a 10-cm
dish). Polybrene was added at a concentration of 8 mg/mL.
The viral vector/polybrene mix was left at room tempera-
ture for 15 min and then added to the MSCs. After 4 h, the
medium on the MSCs was changed. Viral expression was
measurable 72 h after infection. Unless otherwise stated,
the multiplicity of infection (MOI) for expression vectors
was 10, and the MOI for shRNA vectors was 20. Trans-
duction efficiencies of more than 90% were achieved.
Single-cell hESC suspension cultures (5104 cell/mL)
were generated using trypsin treatment. Virus supernatants
were added at an MOI of 20 unless otherwise stated, with
8 mg/mL polybrene, incubated in suspension for 1 h, and
then cells were plated on matrigel using feeder free con-
ditions. eGFP expression was quantified after 7 days using
microscopy and fluorescence-activated cell sorting (FACS)
analysis. Transduction efficiencies of 50% to 60% were
achieved.
Cell analysis
FACS analysis was performed on a Beckton-Dickinson
FACS Calibur machine. The SSEA-4 antibody (Develop-
mental Hybridoma Studies Bank [DSHB], Iowa City, IA)
was used for FACS analysis as recommended by the
manufacturer. Alkaline phosphatase and Oil Red O stain-
ing, indicating osteocytic and adipocytic differentiation,
respectively, were performed as previously described.10
Photographs were taken at a magnification of 100 unless
otherwise stated, using a Nikon Coolpix 995 digital camera.
Differentiated cell marker staining was performed on
hESC embryoid body outgrowths grown on gelatin-coated
glass coverslips. Primary antibodies used were mouse
monoclonal anti-chicken myosin heavy chain (CAT# MF
20, DSHB), mouse monoclonal anti-rat Class III b-tubulin
(TUJ1) (CAT# MMS-435P Covance, DSHB), and mouse
monoclonal anti-a-fetoprotein (AFP) clone C3 (CAT#
A8452, Sigma, Poole, UK). Secondary goat anti-mouse –PE
(DakoCytomation) was used to detect primary antibody.
Western blotting and SSEA-4 expression analysis
SDS-PAGE analysis for survivin expression was per-
formed using electrophoresing samples lysed in Radio-
ImmunoPrecipitation Assay buffer for 2 h at 70 V on a 15%
polyacrylamide SDS gel. Gels were semi-dry transferred
onto nitrocellulose membranes and blocked for 1 h in milk.
After overnight incubation with primary mouse anti-survivin
antibody (Cell Signaling Technology, Danvers, MA), mem-
branes were thoroughly washed in phosphate-buffered saline
and 0.05% Tween-20 and incubated for 1 h with secondary
goat anti-mouse horseradish peroxidase (Cal Biochem).
Membranes were then washed and developed using ECL
Plus (Amersham Biosciences, Buckinghamshire, UK) as
described by the manufacturer.
RESULTS
Lentiviral infection of human stem cells
Lentiviral vectors can efficiently transduce a wide range
of cell types, including human stem cells.7,8,13 We inves-
tigated whether a self-inactivating lentiviral vector (pSIN),
which was originally developed for use with hematopoi-
etic stem cells,14 could be used for efficient transduction of
hESCs and primary bone marrow–derived MSCs. All
vectors described in this study were tested on hESC lines
HSF-6 and H9 (National Institutes of Health codes UC06
and WA09, respectively). Both cell lines gave similar re-
sults, and therefore only representative experiments from
H9 are presented here.
The level of transgene expression is dependent on the
type of promoter used and is variable between different cell
types. We therefore tested a range of promoters in MSCs
and hESCs to identify a promoter that is universally highly
expressed in both cell types. We constructed a series of
minimal constructs in which the cytomegalovirus (CMV),
the SFFV, elongation factor 1 alpha (EF1a), or the human
b-actin promoter drove GFP expression (Fig. 1A). Virus
generated from these vectors was pseudotyped with the ve-
sicular stomatitis virus G-protein.15 GFP expression levels
were quantified using FACS analysis after infection of cells
at an MOI of ten 293T infectious units per cell. Results are
expressed as percentage of cells that are enhanced GFP
(eGFP) positive, which should be interpreted as the per-
centage of cells in which the promoter gave a strong en-
ough expression to cause cells to fluoresce above the
background level. After infection of MSCs and hESCs,
qPCR was used to ensure that the average viral copy
number per cell for each of the promoter constructs was
equivalent for each cell line (data not shown).
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MSCs showed an expression pattern similar to that ob-
served for other adherent cell lines (CMV> SFFV>EF1a>
b-actin) (Fig. 1B). However, hESCs showed a different
pattern (SFFV>CMV> b-actin>EF1a). By staining the
cells for stage-specific embryonic antigen (SSEA)-4 (cell
surface marker highly expressed on undifferentiated
hESCs10), we were able to determine the level of GFP ex-
pression within the differentiated and undifferentiated pop-
ulations (Fig. 1C). SSEA-4 low cells consisted of hESCs and
the murine feeder cells used for supporting hESC growth.
FIG. 1. Lentiviral infection of human stem cells: (A) The pMIN vectors containing only the minimal elements required for expression
and 1 of the 4 promoters shown (LTR, long terminal repeat; eGFP, enhanced green fluorescent protein) (B) FACS analysis of eGFP
expression (FL-1) in MSC infected with pMIN promoter constructs. (C) FACS analysis of eGFP expression (FL-1) and SSEA-4
expression (FL-2) of hESC infected with pMIN promoter constructs. Control panel represents mock infected cells. (D) Map of lentiviral
constructs used (LTR, long terminal repeat; cPPT, central polypurine tract; SFFV, spleen focus forming virus; eGFP, enhanced green
fluorescent protein; WPRE, woodchuck hepatitis virus post-transcriptional regulatory element) (E) Effect of MOI on % eGFP ex-
pressing hESC and MSC transduced with pSIN-eGFP.
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However, because of the method of infection, more than 95%
of transduced cells were hESCs. For all the promoters, the
greatest shift in fluorescence intensity was associated with
the differentiated cells (SSEA-4 low). Only a small per-
centage of cells were expressing GFP strongly enough to be
detectable in the undifferentiated population, with the SFFV
promoter giving the highest levels of GFP expression (2%
cells GFP positive). The EF1a promoter, previously shown
to be a strong promoter in undifferentiated hESCs,7 gave the
second highest level of expression (1% GFP-positive cells in
the undifferentiated population). We therefore decided to use
the SFFV promoter in the further studies because of its high
expression in MSCs and hESCs.
Previous studies have shown that the incorporation of a
central polypurine tract (cPPT)16 and woodchuck hepatitis
virus post-transcriptional regulatory element (WPRE)17 can
increase transgene expression levels. By incorporating these
elements into the lentiviral backbone (Fig. 1D), we were
FIG. 2. Lentiviral transgene expression in stem cells is stable throughout differentiation: Cells were transduced with pSIN-eGFP. (A)
FACS profiles of MSC and hESC showing stable expression of eGFP 6 weeks after infection with pSIN-eGFP. (B) Morphology of MSC
transduced at a MOI 10 and differentiated into adipocytes and osteocytes. hESC transduced at a MOI 20 and differentiated to EB and EB
outgrowths. Scale bar represents 200 mm. (C) Colocationation of eGFP with a-fetoprotein, myosin heavy chain, and b-tubulin III by
cofocal microscopy of EB outgrowths. Scale bar represents 50 mm.
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able to enhance the level of GFP expression driven by the
SFFV promoter in MSCs and hESCs (Fig. 1E). Expression
of eGFP could be detected at high levels in MSCs and
hESCs transduced with pSIN-eGFP. When MSCs were
infected at an MOI of 10 and hESCs at an MOI of 20,
expression could be detected in 88% of MSCs and 57% of
hESCs using FACS analysis, and using microscopy, the
transduced cells retained a normal morphology. This expres-
sion was stable for longer than 6 weeks (Fig. 2A). Transduced
hESCs maintained expression of pluripotency-associated
markers SSEA-4 and Tra-1-60 when grown in the undiffer-
entiated state (data not shown). Increasing the MOI further
did not enhance the infection in MSCs, although the fre-
quency of transduced hESCs could be increased to 86% by an
MOI of 50 (data not shown). By using selective mechanical
dissociation of eGFP-positive hESC colonies from cultures
transduced at an MOI of 10, we could select cultures in which
more than 90% of cells were eGFP positive.
Transgene expression during differentiation
To determine whether lentiviral infection had any ad-
verse effect on stem cell function, we assessed the potential
of MSCs and hESCs to differentiate after infection with
pHR-SIN-eGFP. When MSCs were transduced at an MOI
of 10, no change in cell doubling time or viability was
detected during propagation of the cells (data not shown).
In addition, transduced cells retained the ability to differ-
entiate to adipocytic and osteogenic lineages (upon induc-
tion), with transgene expression maintained throughout the
assay (Fig. 2B). Differentiation of MSC was assessed using
oil red O staining of lipid droplets in adipocytes or the
expression of alkaline phosphatase as a marker for osteo-
genic differentiation.18
Differentiation potential of hESCs was assessed using
embryoid body (EB) formation.19 When hESCs are grown
in suspension culture, in conditions permissive for differ-
entiation, they form tight cell aggregates termed EBs, which
consist of differentiated cell types of all 3 germ layers.
In agreement with previous reports,8 transduced hESCs
formed typical EBs upon induction, and when transferred to
adherent culture conditions, outgrowths from the EBs
contained a diverse range of cell morphologies, including
neural-like projections and beating cardiomyocytes (Fig.
2C). Concomitant with differentiation, hESCs lost expres-
sion of cell surface markers (SSEA-3, SSEA-4, TRA-1-60,
and TRA-1-81) characteristic of the pluripotent state (data
not shown). We confirmed that transduced hESCs were
pluripotent using immunostaining and confocal micros-
copy, which was used to co-localize GFP expression with
markers of endoderm (a-fetoprotein), mesoderm (myosin
heavy chain), and ectoderm (b-tubulin III) in EB out-
growths (Fig. 2C). These results show that the SFFV pro-
moter is not silenced during differentiation and hence is a
good promoter for use with stem cells.
At high viral titers, where the MOI was greater than 20,
MSCs and hESCs retained markers of the undifferentiated
state, but these cells started to show aberrant growth charac-
teristics and failed to differentiate normally (data not shown).
Because of the adverse effect infection at high MOI, we rou-
tinely used MOI less than 20 in all subsequent experiments.
Bi-cistronic transgene expression
Lentiviral vectors currently used with stem cells are only
capable of single transgene expression. However, in other
vector systems, multiple transgene expression has been
achieved by linking the expression of 2 genes using an
internal ribosomal entry site (IRES).20 This system has
been shown to require additional cellular cofactors; hence,
expression is cell-type dependent. We therefore modified
the lentiviral backbone to determine whether bi-cistronic
gene expression was functional in stem cells. DsRed and
eGFP were cloned into the pSIN backbone separated by the
human encephalomyocarditis virus IRES (Fig. 3A).21
Although this construct was functional in 293 cells (data
not shown), we found that MSCs transduced with this vector
failed to express DsRed cloned upstream of the IRES ele-
ment. This defect could be corrected by separating the up-
stream gene from the IRES element using a 50 bp linker,
allowing comparable levels of eGFP and DsRed expression
in MSCs and hESCs (Fig. 3B, C). The requirement for a
50 bp linker to achieve functional bi-cistronic expression was
surprising but could be explained by the secondary structure
of the IRES element and the close proximity of the 3@ end of
the DsRed cistron close to the IRES structure causing pre-
mature termination of translation.
hESCs showed a marked toxicity to DsRed, reducing the
efficiency with which red-IRES-green–positive colonies
could be isolated. Further transfection and infection ex-
periments showed this to be a DsRed and not a lentiviral or
IRES-related problem (data not shown). Using DsRed2,
which has recently been reported to have minimal toxic
effect in hESCs, could potentially alleviate this problem.22
Functional RNA interference in stem cells
It has been shown that lentiviral vectors are able to de-
liver RNA interference (RNAi) to human primary and
murine stem cells.23 Recently, it was also shown that len-
tiviral vector–mediated RNAi can efficiently suppress gene
expression in undifferentiated hESCs, although it was not
reported whether this suppression was stable during dif-
ferentiation.9 We therefore expanded previous studies by
confirming that shRNA delivered by our lentiviral vector
was functional in hESCs and MSCs and demonstrating that
co-expression of a drug resistance marker could be used to
select for transduced cells. We also assessed the extent of
gene suppression during differentiation.
To test this, we produced lentiviral constructs encoding a
human U6 promoter and a short hairpin targeting eGFP or
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LacZ as a control (Fig. 4A). This construct also contained a
puromycin resistance cassette driven from the SFFV pro-
moter. We initially chose to target eGFP expression because
changes in fluorescence can be easily quantified at the single
cell level, and down-regulation of eGFP expression has been
shown not to alter viability or growth of stem cells.24 The
shRNA target sequences chosen had no sequence similarity
to any other gene as determined using BLAST analysis.
We generated MSC and hESC lines stably expressing GFP
by transduction with pSIN-SFFV-eGFP. These cells were
subsequently infected with pSINPuro-sh-LacZ or pSIN-
Puro-sh-eGFP (MOI 10) and treated with puromycin to se-
lect for stably transduced cells. After 10 days of selection,
lower eGFP expression was visible in cells transduced with
sh-eGFP (Fig. 4B) with a 90% reduction in fluorescence
intensity was observed using FACS analysis (Fig. 4C). In
contrast, cells infected with the control sh-LacZ construct
showed no reduction in eGFP expression. These results
confirm that lentiviral vectors co-expressing shRNA and a
drug selection marker are functional in human stem cells.
To determine whether RNAi was stable during differen-
tiation, the above cells were induced to differentiate. Trans-
duced MSCs showed normal differentiation to adipocytes
and osteocytes, demonstrating that neither double viral in-
fection nor the cellular process of RNAi interfered with stem
cell function (Fig. 5A). Silencing was stable throughout
differentiation, whereas eGFP expression was unaffected in
the control pSINPuro-sh-LacZ cells. Similarly, transduced
hESCs showed no deleterious effects from shRNA expres-
sion, as assessed using normal EB formation, with stable
FIG. 3. Functional bi-cistronic transgene expression in MSC and hESC. (A) Maps of lentiviral constructs used (LTR, long terminal
repeat; cPPT, central polypurine tract; SFFV, spleen focus forming virus; eGFP, enhanced green fluorescent protein; DsRed, red
fluorescent protein; IRES, internal ribosomal entry site); (B) Site of insertion of 50 bp linker in pSIN-RIGþ. (C) Infection of MSC and
hESC with pSIN-RIG (no linker) and pSIN-RIGþ (with the linker) demonstrating the requirement for a 50 bp linker for bicistronic
expression in stem cells. Scale bars represent 200mm. (Color images available online at www.liebertpub.com/ten.)
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silencing of eGFP expression throughout culture and dif-
ferentiation (Fig. 5B).
Single vector knock-in knock-out
Finally, we assessed the ability of a single vector to si-
multaneously express and inhibit gene function in stem
cells. We created a vector pSINeGFP-sh-survivin encoding
eGFP and a short hairpin targeting survivin, an endogenous
anti-apoptotic gene25 (Fig. 4A). MSCs infected with pSI-
NeGFP-sh-survivin showed an efficient knockdown of
survivin levels with a simultaneous expression of eGFP
(Fig. 5C). This vector was also functional in hESCs, where
stable reduction in endogenous survivin levels concomitant
with expression of eGFP was observed (Fig. 5C).
DISCUSSION
Our inability to manipulate and control stem cell func-
tion hampers the translation of stem cell biology to clinical
practice. Given the recent use of viral vectors for ex vivo
FIG. 4. shRNA functions to silence gene expression in adult stem cells. (A) The lentiviral vector construct used and the target
sequences against eGFP, LacZ, and survivin. (B) knockdown of eGFP expression in MSC (top) and hESC (bottom). Scale bar represents
200 mm. (C) FACS analysis of RNA interference in MSCs and hESCs showing 90% reduction in fluorescence intensity. (Color images
available online at www.liebertpub.com/ten.)
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manipulation of stem cells in clinical trials,26 we therefore
investigated whether a series of lentiviral vectors could be
used to manipulate gene expression in pluripotent hESCs
that have the potential to differentiate into all cell types and
in adult MSCs that are lineage restricted to mesoderm fates.
Although it has been previously reported that lentiviral
vectors can transduce both cell types,7,8,13 we wanted to
expand these studies further by demonstrating that modified
lentiviral vectors can be used for complex manipulation of
stem cell gene expression.
The pSIN vectors used in this study are based on the hu-
man immunodeficiency virus-1 genome and are considered to
be the safest currently available because of the extensive
deletions abolishing self-replication and its ability to recom-
bine with wild-type viruses.27 In agreement with previous
reports, we found that pSIN-based vectors could efficiently
transduce MSCs at low MOI, whereas hESCs were more
recalcitrant to infection. At low viral input (MOI < 20), we
observed no detectable defects in MSC and hESC function.
This was assessed using in vitro differentiation of MSCs to
FIG. 5. Stability of RNAi during differentiation and single vector knock-in/knock-out. (A) MSC infected with pSIN-eGFP and then with
either pSINPuro-sh-LacZ (control) or pSINPuro-sh-eGFP (eGFP target). Cells were induced to differentiate into adipocytes (top) or
osteocytes (bottom) showing that the reduction in eGFP expression is stable throughout differentiation; (B) inhibition of eGFP expression
in hESC during EB outgrowth formation; (C) Western blot of MSC and hESC infected with pSINeGFP-sh-survivin showing simultaneous
eGFP expression and survivin inhibition. Scale bars represent 200mm. (Color images available online at www.liebertpub.com/ten.)
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osteocytes and adipocytes and by the ability of hESCs to
form EBs, which upon prolonged culture, gave rise to a range
of cell morphologies that stained positive for cell markers
specific for mesoderm, endoderm, and ectoderm fates, as well
as producing cells with functional characteristics, such as
pulsating cardiomyocytes. This is in agreement with a pre-
vious study that showed no defects in hESC differentiation
in vitro (EB formation) or in vivo (teratoma formation).8
However, at higher viral loads, we observed aberrant cell
function in MSCs and hESCs. We presume that these effects
are due to genomic damage as a result of multiple viral in-
sertions, highlighting the need for further studies to assess the
effect of viral copy number on stem cell function.
Although transduction frequencies of up to 90% have been
reported in hESCs using high (MOI> 20) viral input,6 it is
clear from our results that such cells are likely to have a
reduced differentiation capacity, despite showing unaltered
growth behavior in the undifferentiated state. Surprisingly,
these cells maintained expression of pluripotent markers,
despite being unable to form EBs, demonstrating the risk of
using marker expression as the sole criterion for pluripotency.
To retain differentiation potential after viral transduction of
hESCs, it was necessary to use low MOI. This led to reduced
infection efficiency; however, pure populations of transduced
cells could be enriched using selection procedures such as
mechanical dissociation of individual colonies or by the use of
a drug selection marker. Using such procedures, we have been
able to produce pure cultures of hESCs expressing eGFP,
using an MOI of as low as 5 (data not shown).
Lentiviral vectors currently developed for use with MSCs
and hESCs are relatively simple, typically permitting the
expression of single transgenes. However, complex ma-
nipulation of stem cell function will probably require ex-
pression of multiple genes, which, using current vectors,
would require multiple viral insertions, increasing the risk
of adverse effects from high viral load. We found that
multiple transgenes could be expressed from a single vector
using a modified IRES element that avoids the need for
cumbersome dual-promoter cassettes. This could be used to
express multiple transgenes to manipulate stem cell function
or, alternatively, permit the linkage of a selection marker
(eGFP or drug selection) to transgene expression.
Gene function studies in human tissues using current
approaches are difficult and laborious. The discovery of
RNAi, in which the expression of small double-stranded
RNA molecules can be used to specifically knock-down
expression of targeted genes, has recently revolutionized
the field. Knock-down of gene expression using shRNA has
been demonstrated in hESCs and MSCs.19 However, these
studies have not addressed whether stable expression of
shRNA from a lentiviral vector has any deleterious effects
on stem cell function. We modified the lentiviral backbone
to express shRNA driven from the U6 promoter. Using this
vector, we were able to show specific stable suppression of
eGFP expression in MSCs and hESCs with no alteration in
the ability of the transduced cells to differentiate. In addi-
tion, we were able to show that co-expression of a drug
selection marker with the shRNA from the lentiviral
backbone allowed rapid selection of transduced cells ex-
pressing the shRNA.
The ability to knock-in/knock-down targeted genes of-
fers a real potential to extend gene therapy to conditions
that require complex gene manipulation. This notion could
be extended to the control of stem cell differentiation, in
which lineage commitment often involves the concomitant
induction and inhibition of signaling pathways. Using the
lentiviral backbone, we demonstrated the feasibility of sin-
gle-vector knock-in/knock-down manipulation by creating
pHR-SINeGFP-sh-survivin, which expresses eGFP from the
SFFV promoter and shRNA, targeting the endogenous anti-
apoptotic gene survivin. This vector was functional in
MSCs and hESCs with altered gene expression stable
throughout differentiation. The ability to stably knock- down
survivin demonstrates that lentiviral-delivered shRNA is an
effective tool for inhibiting endogenous gene expression and
that survivin is non-essential for normal growth and differ-
entiation of MSCs and hESCs.
In conclusion, we have shown that lentiviral-based vectors
can be used for the complex manipulation of gene expression
in human adult and embryonic stem cells. This technology
will enable the systematic analysis of gene function in stem
cells and could potentially be used to control cell fate. In
addition, the application of RNAi in human embryonic stem
cells could be used to mimic genetic disorders and could
potentially be exploited therapeutically.
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